A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE

CompletedOBSERVATIONAL
Enrollment

177

Participants

Timeline

Start Date

July 5, 2021

Primary Completion Date

October 31, 2021

Study Completion Date

January 31, 2022

Conditions
Refractory AMLRelapsed Adult AMLFLT3-TKD MutationFLT3-ITD
Trial Locations (38)

Unknown

Amiens CHU, Amiens

Angers CHU, Angers

Avignon CH, Avignon

Bayonne CH, Bayonne

Besançon CHU, Besançon

Brest CHU, Brest

Caen CHU, Caen

CERGY PONTOISE - CH René Dubos, Cergy-Pontoise

CHU Estaing, Clermont-Ferrand

Corbeil-Essonnes - Ch Sud Francilien, Corbeil-Essonnes

Créteil CHU HENRI MONDOR, Créteil

Dijon CHU, Dijon

Grenoble CHU, Grenoble

Le Mans CH, Le Mans

Limoges CHU, Limoges

Lyon sud CHU, Lyon

Marseille IPC, Marseille

Meaux CH de l'Est francilien, Meaux

METZ-THIONVILLE CHR- Hôpital de Mercy, Metz

Montpellier - Chu Saint Eloi, Montpellier

Nantes CHU, Nantes

Nice CHU, Nice

Nimes CHU, Nîmes

Paris La Pitié salpetrière, Paris

Paris Necker, Paris

Paris Saint Louis, Paris

Bordeaux CHU, Pessac

Reims CHU, Reims

Rennes CHU, Rennes

roubaix CH, Roubaix

Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez

Saint Quentin CH, Saint-Quentin

Toulouse - IUCT Oncopole - Service d'Hématologie, Toulouse

Tours CHU, Tours

Troyes CH, Troyes

Nancy CHU, Vandœuvre-lès-Nancy

Versailles CH, Versailles

Villejuif IGR, Villejuif

All Listed Sponsors
collaborator

Acute Leukemia French Association

OTHER

lead

French Innovative Leukemia Organisation

OTHER